Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1385 - Phase 1/2 Study Of The Selective TRK Inhibitor Larotrectinib, In Pediatric Patients With Cancer

Date

11 Sep 2017

Session

Poster display session

Presenters

Soledad Gallego Mélcon

Citation

Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367

Authors

S. Gallego Mélcon1, M. Casanova2, S. Bielack3, J. Chisholm4, C.S. van Tilburg5, N. Federman6, C.M. Albert7, L. Mascarenhas8, B. Turpin9, R. Nagasubramanian10, N. Shukla11, S. Spunt12, M.C. Cox13, D.S. Hawkins7, A.S. Pappo14, F. Doz15, G. Bisogno16, S.G. Dubois17, T.W. Laetsch18, B. Geoerger19

Author affiliations

  • 1 Pediatric Oncology, Hospital Universitario Vall d’Hebron, 08035 - Barcelona/ES
  • 2 Pediatric Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milano/IT
  • 3 Oncology, Klinikum Stuttgart - Olgahospital, 70174 - Stuttgart/DE
  • 4 Pediatric Oncology, The Royal Marsden Hospital, Sutton/GB
  • 5 Pediatric Oncology, Heidelberg University Clinic and German Cancer Research Center, Heidelberg/DE
  • 6 Pediatric Oncology, University of California, Los Angeles, Los Angeles/US
  • 7 Pediatric Oncology, Seattle Children’s Hospital, University of Washington, Fred Hutchinson Cancer Research Center, Seattle/US
  • 8 Pediatric Oncology, Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles/US
  • 9 Pediatric Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati/US
  • 10 Pediatric Oncology, Nemours Children's Hospital, Orlando/US
  • 11 Pediatric Oncology, Memorial Sloan-Kettering Cancer Center, New York City/US
  • 12 Pediatric Oncology, Stanford University, Palo Alto/US
  • 13 Clinical Development, Loxo Oncology, 94080 - South San Francisco/US
  • 14 Pediatric Oncology, St Jude Children’s Research Hospital, Memphis/US
  • 15 Pediatric Oncology, Institut Curie, Paris/FR
  • 16 Pediatric Oncology, Padova University, Padova/IT
  • 17 Pediatric Oncology, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston/US
  • 18 Pediatric Oncology, University of Texas Southwestern Medical Center at Dallas, 75390-8576 - Dallas/US
  • 19 Pediatric Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
More

Resources

Abstract 1385

Background

Neurotrophin ligands and their receptors TRKA, TRKB, and TRKC (encoded by NTRK1, NTRK2, and NTRK3) are important for growth regulation, differentiation and survival of neurons. Translocations involving the NTRK1/2/3 kinase domain have been described in a broad range of adult and pediatric tumors, including infantile fibrosarcoma (IFS), spindle-cell sarcoma, congenital mesoblastic nephroma, pediatric papillary thyroid cancer, high- and low-grade gliomas and Ph-like acute lymphoblastic leukemia. Larotrectinib is the first small-molecule selective inhibitor of TRKA, -B, and -C in clinical development and has demonstrated tumor growth inhibition in preclinical models and clinically meaningful and durable responses in patients with NTRK-translocated cancers in an adult phase 1 trial.

Trial design

We have initiated an open-label, multi-center, international Phase 1/2 study with larotrectinib in pediatric patients with solid tumors and primary CNS tumors. A pediatric recommended phase 2 dose of 100mg/m2 (caped at 100mg BID) has been established. Enrollment to phase 2 began in April 2017 and is ongoing. For the phase 2 component, patients from 1-month of age with IFS or an NTRK-fusion positive tumor, including those who have not undergone definitive surgery are eligible. Patients who have not undergone definitive surgery are eligible as well. Larotrectinib is administered as an oral liquid formulation or capsules twice daily on a continuous 28-day schedule. Dosing is based on body surface area. The phase 2 portion enrolls patients with NTRK-translocated tumors and measurable disease into three cohorts: 1) infantile fibrosarcoma; 2) other extracranial solid tumors; and 3) primary CNS tumors. The primary endpoint is objective response rate, with duration of response and progression free survival as secondary efficacy endpoints. Quality of life measures and ctDNA are exploratory endpoints. Each phase 2 cohort will enroll in a single stage of up to 10 patients. Molecular abnormalities will be characterized through the analysis of archival tissue.

Clinical trial identification

NIH: NCT02637687; EudraCT #: 2016-003498-16

Legal entity responsible for the study

Loxo Oncology, Inc.

Funding

Loxo Oncology, Inc

Disclosure

M.C. Cox: Employee and stockholder of Loxo Oncology, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.